Cite
HARVARD Citation
Chiorean, M. et al. (n.d.). DOP41 Efficacy and safety of open-label treatment with tofacitinib 10 mg twice daily in patients with ulcerative colitis with clinical response, but not remission, after 52 weeks of maintenance therapy: data from the OCTAVE studies. Journal of Crohn's and colitis. pp. S049-S050. [Online].